[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558913":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":18,"collaborators":7,"id":22,"slug":23,"hasResults":24,"nctId":25,"briefTitle":26,"officialTitle":27,"acronym":7,"eligibilityCriteria":28,"healthyVolunteers":24,"sex":29,"minAge":30,"maxAge":7,"enrollmentInfo":31,"targetDuration":7,"studyType":34,"phases":7,"briefSummary":35,"conditions":36,"keywords":7,"overallStatus":38,"whyStopped":7,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":7},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","BTK inhibitor","patients with treatment naive or R\u002FR CLL who treatment with BTK inhibitor",[14],{"name":15,"role":16,"phone":7,"phoneExt":7,"email":17},"Shengmiao Yang, MD","CONTACT","yangshenmiao@hotmail.com",{"type":19,"investigatorFullName":20,"investigatorTitle":21,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Xiao-Jun Huang","Prof.","100558913","the-real-world-study-of-btk-inhibitor-in-the-treatment-of-chronic-lymphocytic-leukemia-in-china-100558913",false,"NCT06557304","The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China","This is a Multicenter, Retrospective Real-world Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China","Inclusion Criteria:\n\n1. Patients aged ≥18 years old\n2. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL \\[International Workshop on Chronic Lymphocytic Leukemia\\] criteria)；\n3. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on BTK inhibitor;\n4. Prior or current use of BTK inhibitor for ≥3 months\n5. At least one follow-up was recorded during BTK inhibitor treatment","ALL","18 Years",{"count":32,"type":33},1000,"ESTIMATED","OBSERVATIONAL","This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China",[37],"CLL","NOT_YET_RECRUITING","2024-08-19",{"date":41,"type":42},"2024-08-21","ACTUAL",{"date":44,"type":33},"2024-09-01",{"date":46,"type":33},"2027-12-30",{"name":5,"class":6}]